Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2007-02-20
2007-02-20
Weber, Jon (Department: 1657)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
Reexamination Certificate
active
10398677
ABSTRACT:
The present invention is directed to a method to prevent or reduce postoperative corneal subepithelial haze after excimer laser photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK) surgery. According to the method, a therapeutically effective amount of one or more plasminogen activators, most preferably urokinase (uPA), is administered topically to the surface of the affected eye at levels between 0.1 and 2,500 IU/ml, about eight to twelve times on the day of surgery, and four to eight times per day for about the next six to twelve days thereafter. The most preferred therapeutic amount is from about 0.1–1 IU uPA/ml, and also 1–10 IU/ml. Plasminogen activators that can be used in the inventions include urokinase, prourokinase, streptokinase and mutants thereof. The invention also covers topical ophthalmic compositions that include one or more plasminogen activators, most preferably uPA, to prevent or reduce postoperative corneal subepithelial haze.
REFERENCES:
patent: 6737075 (2004-05-01), Karageozian
patent: 2002/0119141 (2002-08-01), Karageozian
patent: 199 01 594 (2000-08-01), None
patent: WO 00/66139 (2000-11-01), None
Csutak et al. 2004. INvestigative Opthalmology & Visual Science, May, vol. 45, No. 5, pp. 1329-1333.
Plasminogen Activator Activity in Rabbit Tears after Excimer Laser Photorefractive Keratectomy, A.Csutak, et al., IOVS, vol. 41, No. 4, pp. S69, Mar. 15, 2000.
The Effects of Topical Corticosteroids and Plasmin Inhibitors on Refractive Outcome, Haze, and Visual Performance after Photorefractive Keratectomy, David P.S. O'Brart et al., Ophthalmology, vol. 101, No. 9, Sep. 1994, p. 1565-1574.
Plasmin-and Plasminogen- Activator Inhibitors After Excimer Laser Photorefractive Keratectomy: New Concept in Prevention of Postoperative Myopic Regression and Haze, C.P. Lohmann, MD et al., Refractive & Corneal Surgery, vol. Jul./Aug. 1993.
Results and Complications in rTPA Treatment of the Anterior Segment of the Eye, K.U.Loffler et al.,Ophthalmologe, 94, p. 50-52, Jan. 1997, with English translation.
Berta Andras
Csutak Adrienne
Silver David M.
Tozser Jozsef
Cooch Francis A.
Srivastava Kailash C.
The Johns Hopkins University
Weber Jon
LandOfFree
Plasminogen activator to prevent corneal and subepithelial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Plasminogen activator to prevent corneal and subepithelial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Plasminogen activator to prevent corneal and subepithelial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3812600